Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) today announced that it will present at the 2005 BIO CEO & Investor Conference at 2:00 pm Eastern Time on Wednesday, February 23, 2005 at the Waldorf-Astoria in New York City.

Larry Stambaugh, Maxim's Chief Executive Officer, will present an overview of the Company's business operations and clinical development. A live webcast of the presentation will be available at http://www.maxim.com. Please log onto the website several minutes prior to the start of the live presentation to ensure adequate time for any software download that may be required.

Maxim Overview

Maxim Pharmaceuticals is a biopharmaceutical company that has been dedicated to developing therapeutic candidates to treat cancer and liver disease. Using its proprietary live cell high-throughput screening technology and chemical genetics, Maxim is developing small-molecule apoptosis inducers to treat cancer. This program has produced several lead compounds that are advancing to clinical trials through collaborations or independently. Maxim is also continuing to screen compound libraries to identify new compounds. Ceplene(TM), Maxim's histamine based drug candidate, administered in combination with IL-2 as a remission maintenance therapy, demonstrated an improvement in leukemia free survival in one Phase 3 study of Acute Myeloid Leukemia patients compared to patients receiving no treatment, the current standard of care.

Apoptosis compounds and Ceplene are investigational drugs and have not been approved by the U.S. Food and Drug Administration or any international regulatory agency.